Login / Signup

Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.

Subathra RadhakrishnanCatherine Ann MartinMukul VijKomalavalli SubbiahLexmi Priya RajuGowripriya GowrishankarVidya Harini VeldoreIlankumaran KaliamoorthyAshwin RammohanMohamed Rela
Published in: Immunotherapy (2024)
Primary hepatic sarcomatoid carcinoma (HSC) is an extremely rare and aggressive subtype of primary liver cancer. HSC has uncertain pathogenesis and dismal prognosis with overall survival of only 8.3 months. The molecular alterations of HSC are also not well understood. In this study, the authors describe a patient who presented with a large liver mass. The patient underwent complete surgical resection and histological examination demonstrated HSC, infiltrating the stomach. PD-L1 was strongly positive in the tumor cells. The patient was started on anti-PD-L1 immunotherapy postsurgery and is doing well 15 months after surgical resection. Tumor whole exome sequencing revealed genetic alterations in TP53 , NF2 and MAGEC3 genes, indicating their potential role in tumor development.
Keyphrases
  • case report
  • lps induced
  • gene expression
  • dna methylation
  • copy number
  • inflammatory response
  • combination therapy
  • toll like receptor
  • nuclear factor
  • replacement therapy